ASSESSING THE BENEFIT OF CONTINUOUS TREATMENT IN THE FIRST TRIAL (MM-020): IMPACT OF RESPONSE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

被引：0

作者：

Bahlis, N. ^{[1
]}

Corso, A. ^{[2
]}

Muegge, L. O. ^{[3
]}

Shen, Z. X. ^{[4
]}

Desjardins, P. ^{[5
]}

Stoppa, A. M. ^{[6
]}

Decaux, O. ^{[7
]}

de Revel, T. ^{[8
]}

Granell, M. ^{[9
]}

Marit, G. ^{[10
]}

Nahi, H. ^{[11
]}

Demuynck, H. ^{[12
]}

Huang, S. Y. ^{[13
]}

Basu, S. ^{[14
]}

Ervin-Haynes, A. ^{[15
]}

Leupin, N. ^{[15
]}

Marek, J. ^{[15
]}

Chen, G. ^{[15
]}

Facon, T. ^{[16
]}

机构：

[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[2] Policlin San Mateo Univ Pavia, Pavia, Italy

[3] Univ Klinikum Jena, Klink Inner Med 2, Jena, Germany

[4] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai 200030, Peoples R China

[5] Hop Charles Lemoyne, Longueuil, PQ, Canada

[6] Inst J Paoli I Calmettes, F-13009 Marseille, France

[7] CHRU Hosp Sod Med Interne, Rennes, France

[8] Hop Instruct Armees Percy, Paris, France

[9] Hosp Santa Cree & St Pau, Barcelona, Spain

[10] CHU Bordeaux Hop Haut Leveque, Pessac, France

[11] Karolinska Univ, Huddinge Hosp, Solana, Sweden

[12] Jan Yperman Hosp VZW, Leper, Belgium

[13] Natl Taiwan Univ Hosp, Taipei, Taiwan

[14] New Cross Hosp, Wolverhampton, W Midlands, England

[15] Celgene Corp, Summit, NJ USA

[16] Hop Claude Huriez, Serv Malad Sang, Lille, France

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P277

引用

页码：85 / 86

页数：2

共 50 条

[41] Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients
Tacchetti, Paola
Rocchi, Serena
Barbato, Simona
Zamagni, Elena
Pantani, Lucia
Mancuso, Katia
Rizzello, Ilaria
Cavo, Michele
EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (12) : 1085 - 1098
[42] Inferior Clinical Outcomes with Fixed Duration Therapy for Transplant Ineligible Myeloma Patients: UK Real-World Data in Comparison with First Trial (MM-020)
Sharpley, Faye A.
Djebbari, Faouzi
Kothari, Jaimal
Lynes, John
McLain-Smith, Su
Ramasamy, Karthik
BLOOD, 2017, 130
[43] Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial
White, Darrell
Lipe, Brea
Gironella Mesa, Mercedes
Niesvizky, Ruben
Oriol, Albert
Sureda Balari, Anna
Bhutani, Manisha
Encinas, Cristina
Khan, Abdullah
Amatangelo, Michael
Jin, Kexin
Solomon, Thomas
Hong, Kevin
Amin, Alpesh
Maciag, Paulo
van de Donk, Niels
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S25 - S25
[44] Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone
Horigome, Yuichi
Kamata, Hirotoshi
Michishita, Yusuke
Yokoyama, Maki
Tadera, Noriyuki
Hayama, Kei
Suzuki, Takahiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,
[45] Impact of Early vs Late Relapse in Patients With Newly Diagnosed Multiple Myeloma Ineligible for Transplant: A Phase 3 FIRST Trial Subanalysis
Facon, Thierry
Kotey, Stanley
Tinel, Antoine
Srinivasan, Shankar
Sturniolo, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E228 - E228
[46] Health-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Results from the first trial.
Delforge, Michel
Minuk, Leonard
Eisenmann, Jean-Claude
Arnulf, Bertrand
Canepa, Letizia
Fragasso, Alberto
Leyvraz, Serge
Langer, Christian
Ezaydi, Yousef
Vogl, Dan T.
Giraldo-Castellano, Pilar
Yoon, Sung-Soo
Martins, Angelo
Zarnitsky, Charles
Barbe, Martine Escoffre
Lemieux, Bernard
Proskorovsky, Irina
Ervin-Haynes, Annette L.
Houck, Vanessa
Facon, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[47] A glimpse into transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: carinae study
de Arriba de la Fuente, Felipe
Hernandez Garcia, Miguel Teodoro
Soler Campos, Juan Alfons
Herraez Rodriguez, Susana
Jose Moreno, Ma
Conzalez Pardo, Miriam
Gironella Mesa, Mercedes
Casanova Espinosa, Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S143 - S144
[48] Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: CARINAE study
Casanova Espinosa, Maria
Hernandez Garcia, Miguel Teodoro
Soler Campos, Juan Alfons
Herraez Rodriguez, Susana
Moreno Belmonte, Maria Jose
Gonzalez-Pardo, Miriam
Gironella Mesa, Mercedes
de Arriba de la Fuente, Felipe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S93 - S94
[49] Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis
Thierry Facon
Jesús San-Miguel
Meletios A. Dimopoulos
Maria-Victoria Mateos
Michele Cavo
Sophie van Beekhuizen
Zijiao Yuan
João Mendes
Annette Lam
Jianming He
Eric Ammann
Shaji Kumar
Advances in Therapy, 2022, 39 : 3868 - 3869
[50] Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study
de la Fuente, Felipe de Arriba
Mesa, Mercedes Gironella
Garcia, Miguel Teodoro Hernandez
Campos, Juan Alonso Soler
Rodriguez, Susana Herraez
Belmonte, Maria Jose Moreno
Lopez, Teresa Regueiro
Gonzalez-Pardo, Miriam
Espinosa, Maria Casanova
PHARMACEUTICALS, 2024, 17 (10)

← 1 2 3 4 5 →